{"component": "definition", "props": {"groups": [{"snippet_links": [], "samples": [{"hash": "dZYpWVSqCBW", "uri": "/contracts/dZYpWVSqCBW#additional-target", "label": "Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 31.8446273804, "published": true}, {"hash": "7KONgmwhZym", "uri": "/contracts/7KONgmwhZym#additional-target", "label": "Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7494869232, "published": true}, {"hash": "l0LQbJsnKod", "uri": "/contracts/l0LQbJsnKod#additional-target", "label": "Collaboration and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385349274, "published": true}], "snippet": "has the meaning set forth in Section 3.3(c).", "size": 20, "hash": "e9a9ee7cac793eac8c807f7a3c21b4f1", "id": 1}, {"snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "samples": [{"hash": "jpnZcbP2zYu", "uri": "/contracts/jpnZcbP2zYu#additional-target", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 31.8446273804, "published": true}, {"hash": "ggnshgntmlA", "uri": "/contracts/ggnshgntmlA#additional-target", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7494869232, "published": true}, {"hash": "lgwM84kDb46", "uri": "/contracts/lgwM84kDb46#additional-target", "label": "Research Collaboration, Option and License Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385349274, "published": true}], "snippet": "is defined in Section 2.1.6.", "size": 7, "hash": "142adac2340add27b6ac6250caefec92", "id": 2}, {"snippet_links": [], "samples": [{"hash": "1h63sgnmv2C", "uri": "/contracts/1h63sgnmv2C#additional-target", "label": "Patent License Agreement (Lucira Health, Inc.)", "score": 32.0390129089, "published": true}, {"hash": "iMDkVcUMulE", "uri": "/contracts/iMDkVcUMulE#additional-target", "label": "Patent License Agreement (Lucira Health, Inc.)", "score": 31.893907547, "published": true}], "snippet": "has the meaning set forth in Section 2.03.", "size": 7, "hash": "8f56d6a2442133da9fd4fef8c172d543", "id": 3}, {"snippet_links": [], "samples": [{"hash": "jHT0QKey9ZU", "uri": "/contracts/jHT0QKey9ZU#additional-target", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.0766601562, "published": true}, {"hash": "bwt6xpH3DpL", "uri": "/contracts/bwt6xpH3DpL#additional-target", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.0739212036, "published": true}, {"hash": "7tMLOume5NX", "uri": "/contracts/7tMLOume5NX#additional-target", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.043806076, "published": true}], "snippet": "shall have the meaning set forth in Section 4.1(c)(i).", "size": 4, "hash": "52f32e0507a5ecb8a66cd41d3c081ca4", "id": 4}, {"snippet_links": [{"key": "initial-target", "type": "clause", "offset": [47, 61]}, {"key": "option-exercise-payment", "type": "definition", "offset": [127, 150]}], "samples": [{"hash": "3MZu6I6lBwk", "uri": "/contracts/3MZu6I6lBwk#additional-target", "label": "License and Option Agreement (Spark Therapeutics, Inc.)", "score": 28.1594791412, "published": true}, {"hash": "liqthmZPnfM", "uri": "/contracts/liqthmZPnfM#additional-target", "label": "License and Option Agreement (Selecta Biosciences Inc)", "score": 28.1211490631, "published": true}, {"hash": "8M0kcyiVCW4", "uri": "/contracts/8M0kcyiVCW4#additional-target", "label": "License and Option Agreement (Selecta Biosciences Inc)", "score": 27.9514026642, "published": true}], "snippet": "each of up to four (4) targets (other than the Initial Target) for which Spark has exercised an Option and paid the applicable Option Exercise Payment.", "size": 3, "hash": "098fdfef672dea497247eafa465e4e51", "id": 5}, {"snippet_links": [{"key": "rare-disease", "type": "definition", "offset": [8, 20]}, {"key": "initial-target", "type": "clause", "offset": [43, 57]}, {"key": "at-the-time", "type": "clause", "offset": [82, 93]}, {"key": "by-novartis", "type": "clause", "offset": [108, 119]}, {"key": "pursuant-to-section", "type": "definition", "offset": [120, 139]}, {"key": "additional-target-option", "type": "clause", "offset": [194, 218]}], "samples": [{"hash": "kGW0plT60ER", "uri": "/contracts/kGW0plT60ER#additional-target", "label": "Option and License Agreement (Voyager Therapeutics, Inc.)", "score": 34.1772766113, "published": true}, {"hash": "56ZJ1zgJEQ2", "uri": "/contracts/56ZJ1zgJEQ2#additional-target", "label": "Option and License Agreement (Voyager Therapeutics, Inc.)", "score": 33.3367538452, "published": true}], "snippet": "means a Rare Disease Target, other than an Initial Target, that is: (a) Available at the time of nomination by Novartis pursuant to Section 2.2.3(a); and (b) for which Novartis has exercised an Additional Target Option under Section 2.2.3(b).", "size": 2, "hash": "648b1339cd142e30d99c6e45dd2de016", "id": 6}, {"snippet_links": [{"key": "by-merck", "type": "clause", "offset": [27, 35]}, {"key": "this-agreement", "type": "clause", "offset": [42, 56]}], "samples": [{"hash": "597ofuSxdZ", "uri": "/contracts/597ofuSxdZ#additional-target", "label": "License Agreement", "score": 30.1154346466, "published": true}, {"hash": "6DK5EwZJ9GP", "uri": "/contracts/6DK5EwZJ9GP#additional-target", "label": "License Agreement (Sutro Biopharma Inc)", "score": 29.6570835114, "published": true}], "snippet": "means any Targets proposed by Merck under this Agreement that are not Named Targets.", "size": 2, "hash": "d95aac0451ecb4e2d247c8e649944245", "id": 7}, {"snippet_links": [{"key": "section-33", "type": "definition", "offset": [36, 47]}, {"key": "expansion-option", "type": "definition", "offset": [55, 71]}, {"key": "additional-targets", "type": "clause", "offset": [73, 91]}], "samples": [{"hash": "i9UmgP0NqYf", "uri": "/contracts/i9UmgP0NqYf#additional-target", "label": "Research Collaboration and License Agreement (Kite Pharma, Inc.)", "score": 27.6009578705, "published": true}, {"hash": "kh16RgRIgba", "uri": "/contracts/kh16RgRIgba#additional-target", "label": "Research Collaboration and License Agreement (Kite Pharma, Inc.)", "score": 26.2292957306, "published": true}], "snippet": "shall have the meaning set forth in Section 3.3 (Amgen Expansion Option; Additional Targets).", "size": 2, "hash": "d5b3a520eb485310df3b0eb24614f516", "id": 8}, {"snippet_links": [{"key": "initial-targets", "type": "definition", "offset": [30, 45]}, {"key": "agreed-by", "type": "definition", "offset": [55, 64]}, {"key": "in-accordance-with", "type": "clause", "offset": [80, 98]}], "samples": [{"hash": "aGQDhKZv6uF", "uri": "/contracts/aGQDhKZv6uF#additional-target", "label": "Licence and Supply Agreement (CARGO Therapeutics, Inc.)", "score": 32.8453102112, "published": true}, {"hash": "lzdzxrcvkc6", "uri": "https://investors.cargo-tx.com/static-files/8fdf2c0c-de14-406c-a874-b41c824fe9d3", "label": "Amendment", "score": 15.9472961426, "published": false}], "snippet": "means a target other than the Initial Targets which is agreed by OXB and Client in accordance with clause 2.4;", "size": 2, "hash": "6463109f433821a79913318184380997", "id": 9}, {"snippet_links": [{"key": "subject-of", "type": "clause", "offset": [34, 44]}, {"key": "development-program", "type": "definition", "offset": [57, 76]}, {"key": "in-accordance-with", "type": "clause", "offset": [109, 127]}, {"key": "selection-of-additional-targets", "type": "clause", "offset": [149, 180]}], "samples": [{"hash": "fdWfxTdm9VC", "uri": "/contracts/fdWfxTdm9VC#additional-target", "label": "Collaborative Research and License Agreement (C4 Therapeutics, Inc.)", "score": 31.6913070679, "published": true}, {"hash": "ju0ZIkm1mgR", "uri": "/contracts/ju0ZIkm1mgR#additional-target", "label": "Collaborative Research and License Agreement (C4 Therapeutics, Inc.)", "score": 31.5954818726, "published": true}], "snippet": "means any target that will be the subject of a Candidate Development Program, which targets will be selected in accordance with Section 3.1.1(b)(i) (Selection of Additional Targets) and any alternative splice variants, mutants, polymorphisms, and fragments thereof.", "size": 2, "hash": "cde43718c1ad8ee9be3ef9951296f960", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIaYWRkaXRpb25hbC10YXJnZXQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Additional Target", "snippet": "has the meaning set forth in Section 3.3(c).", "size": 65, "id": "additional-target", "examples": ["During the Target Replacement Period, in accordance with this Section 3.2, Prevail may elect to replace an Initial Target or the <strong>Additional Target</strong> with one other Target identified by Prevail in its discretion.", "Each other Research Plan (including as required in connection with Section 3.1 (inclusion of the <strong>Additional Target</strong>) or Section 3.2 (substitution by a Replacement Target)) shall be prepared by the Parties and become effective once executed by both Parties; [*]."], "related": [["soft-target", "Soft Target", "Soft Target"], ["kpi-target", "KPI Target", "KPI Target"], ["collaboration-target", "Collaboration Target", "Collaboration Target"], ["ebitda-target", "EBITDA Target", "EBITDA Target"], ["m2-target-amount", "M2 Target Amount", "M2 Target Amount"]], "related_snippets": [], "updated": "2026-07-04T05:45:54+00:00"}, "json": true, "cursor": ""}}